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a  b  s  t  r  a  c  t
The  highly  efﬁcacious  human  papillomavirus  (HPV)  vaccines  contain  virus-like  particles  (VLP)  represent-
ing  genotypes  HPV16  and  HPV18,  which  together  account  for approximately  70%  of  cervical  cancer  cases.
Vaccine-type  protection  is  thought  to  be mediated  by  high  titer,  type-speciﬁc  neutralizing  antibodies.  The
vaccines  also confer  a degree  of cross-protection  against  some  genetically-related  types  from  the  Alpha-9
(HPV16-like:  HPV31,  HPV33,  HPV35,  HPV52,  HPV58)  and  Alpha-7  (HPV18-like:  HPV39, HPV45,  HPV59,
HPV68)  species  groups.  Cross-protection  is  coincident  with  the  detection  of low  titer  serum  responses
against  non-vaccine  types  by  vaccinees.  Such  antibodies  may  be the  effectors  of cross-protection  or  their
detection may  be useful  as a correlate  or  surrogate.
This  study  evaluated  whether  cross-neutralization  of HPV  types  from  the  Alpha-9  species  group  is
mediated  by antibodies  with  a predominantly  type-restricted  speciﬁcity  for HPV16 that  nevertheless
exhibit  low  afﬁnity  interactions  with  non-vaccine  types,  or by  antibody  speciﬁcities  that  demonstrate
similar  recognition  of  vaccine  and  non-vaccine  types  but are  present  at very  low  levels.
Antibodies  generated  following  Cervarix® vaccination  of  13–14  year old  girls were  evaluated  by
pseudovirus  neutralization,  VLP ELISA  and  by enrichment  of target  antigen  speciﬁcity  using VLP-
immobilized  beads.  Two-dimensional  hierarchical  clustering  of  serology  data  demonstrated  that  the
antibody  speciﬁcity  proﬁle  generated  by VLP ELISA  was  both  quantitatively  and  qualitatively  different
from  the  neutralizing  antibody  speciﬁcity  proﬁle.  Target-speciﬁc  antibody  enrichment  demonstrated
that  cross-neutralization  of non-vaccine  types  was  due  to  a minority  of  antibodies  rather  than  by
the  weak  interactions  of a  predominantly  type-restricted  HPV16  antibody  speciﬁcity.  Furthermore,
cross-neutralization  of  non-vaccine  types  appeared  to  be mediated  by multiple  antibody  speciﬁcities,
recognizing  single  and  multiple  non-vaccine  types,  and  whose  speciﬁcities  were  not predictable  from
examination  of  the serum  neutralizing  antibody  proﬁle.  These  data  contribute  to  our understanding  of
the antibody  speciﬁcities  elicited  following  HPV  vaccination  and  have  potential  implications  for vaccine-
induced  cross-protection.
Crown  Copyright  ©  2014  Published  by  Elsevier  Ltd.  Open access under CC BY-NC-ND license.. IntroductionThe human papillomavirus (HPV) vaccines, Cervarix® and
ardasil®, comprise virus-like particles (VLP) based upon the major
apsid protein, L1, of HPV16 and HPV18. Both vaccines are highly
fﬁcacious at preventing persistent infection and more progressive
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Open access under CC BY-NCdisease associated with HPV16 and HPV18 [1,2]. Antibodies capa-
ble of neutralizing pseudoviruses representing HPV16 and HPV18
can be detected in the serum and cervicovaginal secretions of vac-
cinees [3–5]. Together with passive transfer studies demonstrating
that immune sera, puriﬁed IgG or monoclonal antibodies (MAbs)
can protect animals against papillomavirus challenge [6–8], has led
to the reasonable assumption that vaccine-induced type-speciﬁc
protection is mediated by neutralizing antibodies [9,10].
A degree of cross-protection has also been demonstrated against
some closely-related types within the Alpha-papillomavirus
species groups, Alpha-9 (HPV16-like: HPV31, HPV33, HPV35,
HPV52, HPV58) and Alpha-7 (HPV18-like: HPV39, HPV45, HPV59,
HPV68) [1,2]. Cross-protection is coincident with the detection
of cross-neutralizing antibodies against these types in the serum
-ND license.
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nd cervicovaginal secretions of vaccinees [4,11–13]. Whether
uch antibodies are effectors, or their detection has some utility
s a correlate or surrogate of vaccine-induced cross-protection is
ncertain.
The antibody response following VLP immunization has been
easured using a VLP enzyme-linked immunosorbent assay
ELISA) [14], a pseudovirus-based neutralization assay [15] and
 competitive Luminex® immunoassay (cLIA) [16]. Different
ntibody speciﬁcities are measured by each of these assays but
he nature of any potential discrepancies are not fully under-
tood [9,11]. The cLIA assay uses the type-restricted murine MAb
16.V5 [17], whose human homologue appears to be the majority
peciﬁcity generated during natural infection [18] and is assumed
o constitute a high proportion of the antibodies elicited during
accination.
The magnitude and breadth of the vaccine-induced serum neu-
ralizing antibody response against non-vaccine types generally
ncreases with the vaccine-type response [4,12,13]. It is unclear
hether cross-neutralization within the Alpha-9 group is facili-
ated by antibodies other than the H16.V5-like human homologue
r that this antibody exhibits some degree of cross-recognition not
resent in the murine version.
In this study we attempted to dissect the serum antibody
esponse generated against non-vaccine types from the Alpha-9
roup following Cervarix® vaccination in order to further describe
he antibody speciﬁcities responsible for cross-neutralization.
. Material and methods
.1. Study samples
Serum samples (n = 69) were collected from 13 to 14 year old
irls a median 5.9 months following their third dose of Cervarix®
12].
.2. L1L2 pseudovirus neutralization assay
L1L2 pseudoviruses representing vaccine-relevant Alpha-9
ypes (HPV16, HPV31, HPV33, HPV35, HPV52 and HPV58) and
arrying a luciferase reporter were expressed from transiently
ransfected 293TT cells, puriﬁed and characterized as previously
escribed [12]. The equivalent of a Tissue Culture Infectious Dose
0% (TCID50) was estimated using the Spearman–Karber equation
nd a standardized input of 300 TCID50 was used for all pseu-
oviruses [12,15]. Serum samples were subjected to 4-5 serial
ilutions and the 80% reciprocal neutralization titer estimated by
nterpolation. A panel of six serum samples were retested against
he six pseudoviruses (n = 36; Pearson’s r = 0.976; p < 0.001) and
emonstrated good inter-assay reproducibility.
.3. L1 VLP ELISA
L1 VLP were expressed using the Bac-to-Bac® Baculovirus Sys-
em (Life Technologies), as previously described [20], wherein the
1 genes shared 100% amino acid sequence identity with the L1
enes of the Alpha-9 pseudovirus clones [12]. The L1 VLP were
sed as target antigens in a ELISA, as previously described [4].
erum samples were subjected to 4–5 serial dilutions and the 50%
eciprocal binding titer estimated by interpolation. Good inter-
ssay reproducibility was demonstrated by retesting a panel of six
erum samples against the six L1 VLP (n = 36; Pearson’s r = 0.947;
 < 0.001)..4. Hierarchical clustering of serology data
Serological and viral dendrograms were generated by calcu-
ating the pairwise Euclidean distances for the Log10-transformed2 (2014) 1139–1146
pseudovirus neutralization assay and VLP ELISA data, generating
distance matrices that were then clustered using a neighbor-
joining algorithm (http://evolution.genetics.washington.edu/
phylip.html). The resulting viral dendrograms were bootstrapped
by resampling the sera data to generate 500 pseudoreplicates. Den-
drograms were viewed using FigTree 1.3.1 (http://tree.bio.ed.ac.uk/
software/ﬁgtree/). The serological data were then represented by
a heat map  ordered according to the resulting serological and viral
dendrograms.
2.5. Antibody adsorption and elution from L1 VLP
VLP (HPV16 10 g; non-vaccine type 5 g) were coupled to
magnetic sepharose beads (GE Healthcare) overnight at 4 ◦C.
Antibody adsorption and elution were performed as described
elsewhere [21,22] with minor modiﬁcations. Sera for adsorption
were diluted ﬁve-fold in Dulbecco’s modiﬁed Eagle medium
(DMEM) containing 10% fetal bovine serum (FBS) (Life Technolo-
gies) and incubated with beads for 1 h at room temperature. The
post-adsorption serum fraction was  separated from the beads
using a magnetic rack before being subjected to a second round
of adsorption using a freshly coupled bead set. Both bead sets
were then washed three times in DMEM containing 10% FBS.
No residual antibody activity was  detectable in the ﬁnal washes.
Antibodies were eluted using 0.1 M glycine–HCI (pH 2.9–1.9) and
neutralized with 1 M Tris–HCI, pH 9 (GE Healthcare). The pooled
eluted antibody fractions were concentrated using Vivaspin 500
columns (GE Healthcare). Each serum was  also subjected to two
rounds of adsorption on, and elution from, beads coupled with
10 g BSA which was  used as a control for non-speciﬁc activity;
when eluted fractions were tested against the HPV16 pseudovirus
they were found to have levels of neutralizing antibody below the
detection threshold.
2.6. Statistical methods
Pearson’s correlation was  used to evaluate the relationship
between HPV16 antibody titers. Fisher’s exact test was used to
determine whether the proportion of sera reactive against a par-
ticular non-vaccine type differed between the two assay systems.
Tests were 2-tailed where appropriate and performed using Stata
12.1 (Statacorp, College Station, TX).
3. Results
Sixty nine serum samples from Cervarix® vaccinees, previously
tested in the pseudovirus neutralization assay against vaccine-
relevant Alpha-9 types [12] were tested against VLP representing
the same HPV types by ELISA.
3.1. Antibody titers measured in pseudovirus neutralization assay
and VLP ELISA
As in the pseudovirus neutralization assay [12], all sera (n = 69,
100%) tested positive for HPV16 antibodies by VLP ELISA. A sig-
niﬁcant correlation was observed between the antibody titers
generated by the pseudovirus neutralization assay (median 19,258
[inter-quartile range, IQR, 11,730–28,132]) and VLP ELISA (9279
[7290–44,719]) (Pearson’s r = 0.833; p < 0.001).
For non-vaccine types, there were differences between antibody
titers generated in the VLP ELISA and the pseudovirus neutral-
ization assay. While the number of samples positive for HPV31
antibodies in the VLP ELISA (n = 58; 84%) and pseudovirus neu-
tralization assay (n = 60; 87%) were similar (p = 0.810), antibody
titers of sera positive in both assays were higher in the VLP ELISA
(median 651 [IQR 576–771]) than in the pseudovirus neutralization
S.L. Bissett et al. / Vaccine 32 (2014) 1139–1146 1141
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og10-transformed pseudovirus neutralization data (centre, heat map) were subje
left)  and pseudovirus (top) dendrograms constructed from the resulting distance 
erological data whereas the pseudovirus target dendrogram clusters are supported
ssay (96 [50–203]) (p < 0.001). More serum samples were posi-
ive for HPV33 antibodies by VLP ELISA (n = 47; 68%) than by the
seudovirus neutralization assay (n = 29; 42%; p = 0.003) with dual
ositive titers higher in the VLP ELISA (600 [374–735]) than in the
seudovirus neutralization assay (29 [25–54]) (p < 0.001).
These data suggest that there were quantitative differences
etween the pseudovirus neutralization assay and VLP ELISA and/or
arget antigens, particularly for non-vaccine types. We  next sought
o evaluate whether these data also reﬂected qualitative differ-
nces.
.2. Hierarchical clustering of serological data
Two-dimensional antigenic dendrograms were constructed by
ierarchical clustering of the pseudovirus neutralization assay
Fig. 1) and VLP ELISA (Fig. 2) data. The target antigens (L1L2 pseu-
ovirus or L1 VLP) were clustered horizontally while the sera were
lustered vertically against a heat map  representing the Log10-
ransformed antibody titer data. This approach allowed us to sort
he pseudovirus neutralization and VLP ELISA data into clusters of
era displaying similar antigenic proﬁles.
The magnitude and breadth of the individual serum neutral-
zing antibody responses against vaccine and non-vaccine typeso two-dimensional hierarchical clustering and re-ordered according to serological
es. The serological dendrogram is labeled I-VIII based upon intuitive clustering of
ootstrapping of 500 pseudoreplicates.
permitted intuitive clustering (Fig. 1). Serum samples in Cluster I
displayed the highest HPV16 neutralization titers and the broadest
coverage of non-vaccine types, while Cluster VI included sam-
ples that had intermediate HPV16 neutralization titers and whose
breadth of reactivity extended to HPV31 and HPV33 (Table 1).
These data support a generally quantitative relationship between
the level of antibodies in vaccinee sera against HPV16 and an ability
to recognize non-vaccine types. However, there also appeared to be
a number of antibody speciﬁcities displayed. Samples within Clus-
ters II, V and VI for example exhibited differential neutralization
of HPV33, HPV35 or HPV52, in addition to HPV31 despite similar
HPV16 antibody titers.
The serological dendrogram based upon VLP ELISA binding titers
(Fig. 2) permitted the formation of branches but the ordering of
individual sera bore little relation to the arrangement in the sero-
logical dendrogram based upon the pseudovirus neutralization
data.
The hierarchical clustering of antibody responses also permit-
ted the ranking of the target antigens. Pseudoviruses HPV31 and
HPV33 were the nearest antigenic relatives to HPV16 followed by
HPV58 (Fig. 1). HPV52 and HPV35 pseudoviruses clustered together
suggesting a close antigenic relationship between these types. The
antigenic dendrogram based upon VLP ELISA data (Fig. 2) was
1142 S.L. Bissett et al. / Vaccine 32 (2014) 1139–1146
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T
Dig. 2. Hierarchical clustering of L1 VLP binding data.
og10-transformed VLP binding data (centre, heat map) were subjected to two-
seudovirus (top) dendrograms constructed from the resulting distance matrices. V
roadly similar such that the nearest antigenic relative to HPV16
as HPV31, followed by two separate clusters of HPV33 and HPV58,
nd HPV35 and HPV52. These inter-type antigenic relationships
ad good bootstrap support and differed somewhat from the inter-
ype genetic distances based upon L1 amino sequence (Fig. 3).
.3. Enrichment of vaccine and non-vaccine antibody speciﬁcitiesPotential differences in cross-neutralizing antibody speciﬁcity
ere addressed by adsorption on, and elution from, individual non-
accine type VLP. We  reasoned that if cross-neutralization was
able 1
ifferential pseudovirus neutralization responses informed by hierarchical clustering.
Cluster n Median (IQR) serum neutralization titers against indicated
HPV16 HPV31 
I 13 74,295 (55,880–122,896) 482 (195–665) 
II  5 20,556 (20,032–20,559) 58 (51–98) 
III  7 9721 (5959–12,954) 31 (27–33) 
IV  10 6953 (4366–11,584) 10 (10–10) 
V  7 18,351 (17,026–25,055) 45 (42–84) 
VI  8 13,302 (11,612–17,578) 108 (57–166) 
VII  6 8275 (6386–11,407) 87 (70–107) 
VIII  13 25,962 (21,195–40,113) 152 (90–399) 
a Median (IQR, interquartile range) neutralizing antibody titers of sera within indicatedsional hierarchical clustering and re-ordered according to serological (left) and
get dendrogram is supported by bootstrapping of 500 pseudoreplicates.
due to antibodies that constitute a minor fraction of the total vac-
cine antibody repertoire, such an approach should enrich for these
speciﬁcities in preference to type-speciﬁc HPV16 antibodies. Six
serum samples (A–F) were selected from Cluster I (Fig. 1) for enrich-
ment and the neutralization titers against pseudoviruses HPV16,
HPV31 and another relevant type were determined prior to and
post enrichment. Antibodies enriched on non-vaccine type VLP dis-The enrichment of sera A–D on a particular non-vaccine type VLP
did not also enrich for antibodies against another non-vaccine type.
Enrichment of serum A on HPV31 or HPV58 VLP yielded antibodies
 HPV pseudovirusa
HPV33 HPV35 HPV52 HPV58
54 (24–87) 22 (10–68) 21 (10–25) 20 (10–32)
23 (10–27) 27 (25–49) 10 (10–25) 10 (10–10)
10 (10–10) 10 (10–10) 10 (10–10) 10 (10–10)
10 (10–10) 10 (10–10) 10 (10–18) 10 (10–10)
10 (10–21) 10 (10–10) 28 (25–35) 10 (10–10)
30 (25–37) 10 (10–10) 10 (10–10) 10 (10–10)
10 (10–10) 10 (10–10) 10 (10–10) 10 (10–10)
10 (10–26) 10 (10–10) 10 (10–10) 10 (10–10)
 intuitive clusters against indicated HPV pseudoviruses.
S.L. Bissett et al. / Vaccine 3
F
p
p
c
m
H
i
r
e
a
t
E
b
r
o
o
w
t
F
a
n
a
a
s
H
a
m
v
w
t
n
4
n
v
t
t
c
o
c
t
n
c
c
tig. 3. Distance matrix based upon L1 amino acid sequence used for both Alpha-9
seudoviruses and VLP, generated using a neighbor-joining algorithm and sup-
orted by bootstrap values.
apable of recognizing HPV16 and only the type used for enrich-
ent. For example, the pre-treatment titers against HPV31 and
PV58 were 211 and 2696, respectively. Enrichment on HPV58 VLP
ncreased the titer against HPV58 to 6188 but no HPV31 antibody
eactivity was detectable. Serum B which demonstrated post-
nrichment neutralization activity against HPV31, HPV33, HPV35
nd HPV58 appeared to comprise multiple antibody speciﬁcities
hat recognized HPV16 and only the indicated non-vaccine type.
nrichment of sera C and D on HPV35 VLP yielded antibodies capa-
le of recognising HPV16 and HPV35, but not HPV31.
Antibodies enriched from serum E and F exhibited cross-
ecognition of more than one non-vaccine type. The enrichment
f serum E on HPV31 or HPV33 VLP yielded antibodies capable
f recognizing HPV16, HPV31 and HPV33 pseudoviruses. Serum F
hen enriched on HPV31, HPV33 and HPV58 demonstrated neu-
ralization of HPV31 pseudovirus to a comparable level, and serum
 antibodies enriched on HPV31 or HPV33 VLP had similar titers
gainst HPV33.
The HPV16 titer dropped by a median 1.8 Log10 (IQR 1.7–2.8;
 = 13) fold following enrichment on non-vaccine VLP. Enriched
ntibody titers against HPV16 were similar to the titers observed
gainst the type used for enrichment, for example antibodies in
erum A when enriched on HPV31 VLP neutralized HPV16 and
PV31 at titers of 861 and 795, respectively.
Antibodies enriched from serum samples A–F, were also tested
gainst L1 VLP representing the same HPV types (Supplementary
aterial S1). Antibody binding titers further conﬁrmed the obser-
ations that non-vaccine type antibodies are a minority species
hich display similar reactivity against HPV16 and non-vaccine
ypes and again highlighted discrepancies between binding and
eutralizing antibody speciﬁcity.
. Discussion
We  undertook a proof of concept study to investigate the cross-
eutralizing antibody speciﬁcities generate in response to HPV
accination. Cross-neutralizing antibodies are elicited in response
o both licensed vaccines, Cervarix® and Gardasil® [4,11–13] and
his is coincident with differential degrees of vaccine-induced
ross-protection [1,2], although a direct link between the two
bservations has not been established. The characterisation of the
ross-neutralizing response beyond antibody titer has been limited
o studies of avidity [23] and the vaccine-type speciﬁcity of cross-
eutralizing antibodies [24]. Sera from Cervarix® vaccinees were
hosen since it is this vaccine that appears to elicit the broadest
ross-neutralization of non-vaccine types [4].
In the present study, sera from Cervarix® vaccinees were shown
o have high antibody titers with broad reactivity against L1 VLP2 (2014) 1139–1146 1143
with homologous L1 sequences to those of the pseudoviruses.
HPV16 neutralizing antibody titers were similar to those gener-
ated in the VLP ELISA corroborating observations in other studies
[5,25]. Agreement between antibody reactivity against L1L2 pseu-
doviruses and L1 VLP representing non-vaccine HPV types was
weaker with VLP ELISA antibody titers generally an order of magni-
tude higher than the corresponding pseudovirus neutralizing titers
[4,26].
To examine the discrepancy between cross-reactive antibody
proﬁles, both sets of serological data were subjected to hierarchi-
cal clustering. This approach has been used for the evaluation of
HIV [27–30], foot and mouth disease virus [31] and H5N1 avian
Inﬂuenza virus [32] antibody speciﬁcities, but we believe this is
the ﬁrst time that this approach has been used to examine HPV
vaccine antibody speciﬁcity. Differences between pseudovirus neu-
tralizing and VLP binding antibody proﬁles were stark. There are
likely several confounding factors that contribute to this outcome
including technical differences between the assays and differences
between the range of binding and neutralizing antibody speciﬁci-
ties generated. Thus, while L1 VLP binding may  be a useful surrogate
for type-speciﬁc vaccine antibody responses [25] they may  not
be a similarly useful surrogate for neutralizing antibody reactivity
against non-vaccine types.
A number of murine MAbs are capable of binding L1 VLP but
lack the ability to neutralize the homologous L1L2 pseudovirus
[17,33–35]. For example, MAb  H16.J4 cross-reacts with L1 VLP
representing various HPV types by ELISA [17], cross-neutralizes
HPV31, HPV33 and HPV58 in an L1-based reporter transduction
assay [36], but poorly recognizes its epitope on HPV16 L1L2 pseu-
doviruses [34,35]. Conversely, the neutralizing type-speciﬁc MAb
H16.V5 appears to recognize its epitope on L1 VLP and L1L2 pseu-
doviruses to a similar extent [35]. It is reasonable to assume,
therefore, that the majority of non-neutralizing antibodies in vac-
cine sera that recognize VLP representing non-vaccine types, bind
to portions of the L1 protein not involved in (pseudo)virus entry or
to domains that become altered when L2 is incorporated into the
capsid.
There was some agreement in the antigenic inter-type ranking
of target HPV types. For both L1 VLP and L1L2 pseudovirus anti-
gens, HPV31 was  ranked as the nearest relative to HPV16, and
both HPV33/HPV58 and HPV35/HPV52 appeared to share some
antigenic similarity, at least based upon reactivity of antibodies
generated against the archetypal Alpha-9 group type, HPV16. Some
of these antigenic similarities could have been predicted from the
distance matrix based upon the L1 amino acid sequence (HPV33
and HPV58), while some could not (HPV35 and HPV52).
Hierarchical clustering of the pseudovirus neutralization data
also suggested that Cervarix® vaccination elicits multiple cross-
reactive antibody speciﬁcities. The underlying basis for individuals
generating such a range of cross-reactive antibody speciﬁcities
is unclear. There may  be a genetic component [37] that could
impact on an individual’s ability to process certain immunogenic
epitopes displayed on the vaccine antigens but identifying such
contributing factors is challenging. In an attempt to examine the
multiplicity of this cross-neutralizing response, we performed anti-
body enrichment of sera using L1 VLP immobilized onto beads and
then tested the eluted fractions against relevant pseudoviruses. The
enrichment of antibody speciﬁcities using this approach appears
to suggest that cross-reactive antibodies formed a distinct, minor-
ity speciﬁcity within the vaccine-induced antibody repertoire and
were not a consequence of a low afﬁnity interaction of an otherwise
predominantly type-speciﬁc antibody.The enriched fractions displayed a range of cross-neutralizing
antibody speciﬁcities including those that recognize multiple non-
vaccine types and those that recognize only single non-vaccine
types. The cross-neutralizing speciﬁcities of the enriched antibody
1144 S.L. Bissett et al. / Vaccine 32 (2014) 1139–1146
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Fig. 4. L1L2 pseudovirus neutralization titers prior to and post antibody enrichment on non-vaccine L1 VLP.
Serum samples (A–F) were enriched on VLP representing non-vaccine A9 types. The neutralization titer against pseudoviruses (PsV) representing HPV16, HPV31 and another
relevant type were determined for the serum samples prior to and post enrichment.
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ractions could not have been predicted from the neutralization
roﬁle of the source serum. These data suggest that there are mul-
iple immunogenic sites on the surface-exposed domains of the
PV16 L1 protein that share sequence and/or structural homol-
gy with other Alpha-9 types. These regions may  include the
ariable loops DE, FG and HI that appear to be common tar-
et domains of antibodies generated by natural HPV16 infection
38].
There are several potential shortcomings to this work. Only
ix sera were evaluated from individuals given Cervarix® vac-
ine. Caution should therefore be employed when attempting to
xtrapolate these ﬁndings to the majority of HPV vaccinees. Extend-
ng this work to include sera from both Cervarix® and Gardasil®
accinees will support a more robust evaluation. The target anti-
ens for the enriched antibodies were L1L2 pseudoviruses whereas
he antigens used for the enrichment were L1 VLP which may
ave introduced some bias in the antibody speciﬁcities being
easured. This approach was used for two reasons. First, in
ur hands, the expression and puriﬁcation of L1 VLP generates
urer populations of antigen than the corresponding puriﬁca-
ion of L1L2 pseudoviruses. Second, the immunogens used in
he HPV vaccines are L1 VLP and so the use of L1 VLP as the
mmobilized antigen should have allowed capture of the major-
ty of L1-speciﬁc antibodies able to recognize a particular HPV
ype. The recovery of high titer cross-neutralizing antibodies fol-
owing enrichment on non-vaccine VLP appears to support the
aintenance of some VLP conformational integrity following bead
mmobilisation.
If cross-neutralizing antibodies form a tiny minority of the anti-
odies elicited following HPV vaccination it is possible that their
eneration and maintenance is more precarious than those of vac-
ine type antibodies. HPV31 cross-neutralizing antibody can be
etected at 18 months after the third Cervarix® vaccine dose sug-
esting some degree of stability in this regard [26]. A two-dose
chedule may  also be an issue for the generation and maintenance
f a sizeable cross-neutralizing antibody fraction. While HPV16
ntibody titers following a two dose schedule appear to be non-
nferior to those following a three dose schedule [19], the impact
n the generation of antibodies to non-vaccine types is unclear.
nderstanding the potential impact of prior infection on vaccine
ntibody responses [23] and differences between the speciﬁcities
f antibodies generated following vaccination and during natural
nfection will also be important.
Overall, these data support the notion that antibody neutraliza-
ion of non-vaccine types by Cervarix® vaccine sera is due to a small
raction of antibodies exhibiting different but overlapping speciﬁci-
ies, rather than a predominantly type-speciﬁc antibody speciﬁcity
hat nevertheless exhibits a small degree of cross-recognition of
on-vaccine types. Identifying the HPV16 L1 domains responsible
or their generation and perhaps improving HPV16 VLP immuno-
enicity toward the generation of such antibodies will be important
f the development of high titer neutralizing antibodies targeting
on-vaccine types is considered to be a desirable outcome of HPV
accination.
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Appendix A. Supplementary data
Supplementary material S1 L1 VLP binding titers prior to and
post antibody enrichment on non-vaccine L1 VLP.
Serum samples (A–F) were enriched on VLP representing non-
vaccine A9 types. The binding titer against VLP representing HPV16,
HPV31 and another relevant type were determined for the serum
samples prior to and post enrichment.
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.vaccine.
2014.01.008.
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